You are here: Home Reviews Loramyc (mikonazole)

Print

Loramyc (mikonazole)


Conclusion

Loramyc is a new type of local treatment of oral candidiasis with mucoadhesive resoriblets, which was marketed the 28th of July 2008. The treatment is 6-7 times more expensive than traditional local treatment with Brentan (miconazole) oral cavity gel and Mycostatin (nystatin) oral suspension and systemic treatment with fluconazole and itraconazole.

 

IRF states that because of the major price difference, limited effect and no greater effect on recurrence of oral or orofaryngeal candidiasis Loramyc should not be the drug of first choice in treatment of these diseases.

 

 

 


To the topTo the top


Page last updated: 20 August 2008 Print Printspacer Tip a friend Tip a friend spacerTo the top To the top